Bausch + Lomb Corporation BLCO
- Market cap
- $6.0B
- P/E
- 0.0×
Follow BLCO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 12.20 | 14.64 | 13.16 | 10.45 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | 20.20 | 21.95 | 21.69 | 18.55 |
High Price
|
|||
| — | — | — | — | — | 12,500 | 12,900 | 13,300 | 13,500 | 13,000 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 3,412 | 3,765 | 3,768 | 4,146 | 4,791 | 5,101 |
Revenue
|
|||
| — | — | — | — | 62.34% | 61.04% | 59.69% | 60.40% | 60.93% | 59.81% |
Gross Margin
|
|||
| — | — | — | — | 290 | 318 | 73 | (166) | (234) | (317) |
EBT
|
|||
| — | — | — | — | 8.50% | 8.45% | 1.94% | (4.00%) | (4.88%) | (6.21%) |
EBT Margin
|
|||
| — | — | — | — | (17) | 193 | 15 | (248) | (305) | (352) |
Net Income
|
|||
| — | — | — | — | 442 | 415 | 387 | 412 | 456 | 439 |
Depreciation
|
|||
| — | — | — | — | 9.75 | 10.76 | 10.77 | 11.83 | 13.62 | 14.42 |
Revenue/Sh
|
|||
| — | — | — | — | (0.05) | 0.55 | 0.02 | (0.74) | (0.90) | (1.02) |
Earnings/Sh
|
|||
| — | — | — | — | 1.49 | 2.49 | 0.99 | (0.05) | 0.66 | 0.80 |
Cash Flow/Sh
|
|||
| — | — | — | — | (0.74) | (0.60) | (0.50) | (0.52) | (0.83) | (0.99) |
Capex/Sh
|
|||
| — | — | — | — | 0.75 | 1.90 | 0.49 | (0.56) | (0.17) | (0.19) |
Free CF/Sh
|
|||
| — | — | — | — | 28.54 | 26.86 | 20.29 | 19.74 | 18.60 | 18.43 |
Book Value/Sh
|
|||
| — | — | — | — | 350 | 350 | 350 | 351 | 352 | 354 |
Shares
|
|||
| — | — | — | — | 38.04 | 38.04 | 786.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 1.86 | 1.86 | 1.46 | 1.43 | 1.33 | 1.18 |
PS Ratio
|
|||
| — | — | — | — | 0.97 | 0.97 | 0.77 | 0.86 | 0.97 | 0.93 |
PB Ratio
|
|||
| — | — | — | — | 2.39 | 2.39 | 2.01 | 2.45 | 2.26 | 2.10 |
EV/Sales
|
|||
| — | — | — | — | 18.13 | 18.13 | 50.72 | (45.55) | (128.83) | (117.89) |
EV/FCF
|
|||
| — | — | — | — | 522 | 873 | 345 | (17) | 232 | 283 |
Op' Cash Flow
|
|||
| — | — | — | — | (259) | (209) | (175) | (181) | (291) | (349) |
Capex
|
|||
| — | — | — | — | 263 | 664 | 170 | (198) | (59) | (66) |
FCF
|
|||
| — | — | — | — | 745 | 536 | 841 | 1,163 | 1,050 | 1,057 |
Working Cap'
|
|||
| — | — | — | — | — | — | 2,436 | 4,562 | 4,784 | 5,082 |
Total Debt
|
|||
| — | — | — | — | (238) | (177) | 2,056 | 4,228 | 4,468 | 4,685 |
Net Debt
|
|||
| — | — | — | — | 9,988 | 9,402 | 7,101 | 6,920 | 6,544 | 6,519 |
Sh' Equity
|
|||
| — | — | — | — | 0.00% | 1.65% | 0.05% | (2.12%) | (2.36%) | (2.62%) |
ROA
|
|||
| — | — | — | — | 1.67% | 2.23% | 1.41% | 0.73% | 0.92% | 0.63% |
ROIC
|
|||
| — | — | — | — | 0.00% | 1.88% | 0.07% | (3.71%) | (4.71%) | (5.51%) |
ROE
|
|||
Bausch + Lomb Corporation peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| STVN Stevanato Group S.p.A. | $5.8B | 37.7× | Compare |
| MMSI Merit Medical Systems, Inc. | $5.2B | 35.7× | Compare |
| TFX Teleflex Incorporated | $5.1B | 0.0× | Compare |
| ATR AptarGroup, Inc. | $7.8B | 22.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ICUI ICU Medical, Inc. | $4.2B | 137× | Compare |
| NVST Envista Holdings Corporation | $3.9B | 40.6× | Compare |
| PLSE Pulse Biosciences, Inc | $3.8B | 0.0× | Compare |
| ALGN Align Technology, Inc. | $10.4B | 25.5× | Compare |
Bausch + Lomb Corporation (BLCO) key facts
- Bausch + Lomb Corporation (BLCO) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
- Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- As of September 25, 2026, BLCO traded at $16.86, a market capitalization of $6.0 billion.
- Return on equity was −5.51% and debt-to-equity 0.79.
Bausch + Lomb Corporation (BLCO) Latest News
14 Sep
Bausch + Lomb gains European CE Mark for next-gen SeeLyra Femtosecond Laser. CE Mark approval for SeeLyra enables European commercialization of advanced femtosecond laser, driving potential revenue growth and market share gains in ophthalmology.
11 Sep
Bausch + Lomb received European CE Mark approval for the SeeLyra femtosecond laser. CE Mark approval enables European market entry for SeeLyra femtosecond laser, potentially boosting sales in ophthalmology segment.
9 Sep
Bausch + Lomb is identified as a cash-producing stock with exciting potential, while two other stocks are flagged to ignore. Positive stock selection as cash producer with potential can moderately lift near-term investor sentiment and trading activity for Bausch + Lomb.
25 Aug
Bausch + Lomb advances two first-in-class eye health therapies. Pipeline progress on first-in-class therapies signals major product launches that can lift revenue and competitive standing.
24 Aug
Bausch + Lomb advances dry eye drug to Phase III trials while its pain candidate meets Phase Ib goals. Pipeline progress on two clinical candidates in core eye-care and adjacent pain areas signals major upcoming catalysts for revenue and positioning.
Bausch + Lomb advances two first-in-class eye health therapies following positive trial results. Positive trial outcomes enable advancement of two innovative therapies, strengthening pipeline and competitive position in core eye health market.
Bausch + Lomb plans to advance its dual-action eye drop targeting evaporative and inflammatory dry eye disease to Phase 3. Pipeline progress on core eye care product may affect innovation and positioning but remains early-stage without immediate financial or market shifts.
7 Aug
Bausch + Lomb Corporation held its Q2 2026 earnings call, covering quarterly financial results, operational updates and forward guidance. Earnings call content supplies key financial metrics and outlook that frequently shift valuation and investor positioning.
6 Aug
Bausch Health CEO Thomas J. Appio joins Bausch + Lomb board. CEO appointment to board signals tighter governance links between Bausch Health and Bausch + Lomb that can shape strategy.
31 Jul
Bausch + Lomb raised its 2026 revenue guidance. The update prompts analysis on whether the stock is still 57% undervalued. Lifting 2026 revenue guidance offers a positive signal that may moderately influence financial outlook and sentiment without fundamentally shifting the company's trajectory.
30 Jul
BHC Q2 earnings beat estimates driven by Salix and Solta growth with 2026 outlook raised. Earnings beat plus raised guidance signals improved performance with moderate effects on company trajectory.
Bausch + Lomb Corporation held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward guidance. Quarterly earnings call delivers performance data and outlook that can shift near-term investor sentiment and valuation.
29 Jul
Bausch Health reported second quarter 2026 results and raised full-year guidance. Raised guidance after quarterly results signals stronger financial outlook and will likely shift investor sentiment and valuation for Bausch + Lomb.
Bausch Health reported second quarter 2026 results and raised full-year guidance. Raised guidance after quarterly results signals stronger financial outlook and lifts investor sentiment for Bausch + Lomb.
Bausch + Lomb Corporation reported broad-based second-quarter growth and raised its full-year 2026 guidance. Broad second-quarter growth combined with raised full-year guidance indicates strong operational momentum and improved financial outlook.
Bausch Health Cos Q2 earnings call highlighted financial results, operational updates, and outlook relevant to Bausch + Lomb Corporation performance and strategy. Q2 earnings details may moderately shape near-term investor views on BLCO finances without indicating major strategic shifts.
Bausch + Lomb Q2 earnings call covered financial results, revenue figures, segment performance, and forward guidance on operations and strategy. Q2 earnings and guidance directly inform near-term financial trajectory and investor views.
Bausch + Lomb Corporation posted strong revenue growth during its Q2 2026 earnings call. Strong Q2 2026 revenue growth can lift near-term financial results and investor views without reshaping long-term strategy.
Bausch + Lomb exceeded Q2 CY2026 expectations. Beating quarterly expectations typically improves near-term stock valuation and investor sentiment.
28 Jul
Bausch + Lomb (BLCO) is scheduled to report earnings tomorrow, with market focus on expected financial results and potential share price reaction. Scheduled earnings release can shift near-term investor views and trading activity for the company.
20 Jul
Bausch + Lomb launches EyeGility Inserter for enVista IOLs in the U.S. Product launch enhances enVista IOL offerings but represents incremental rather than transformative advancement.
16 Jul
Bausch + Lomb Corporation launches the EyeGility Inserter Preloaded IOL Delivery System in the United States. New preloaded IOL delivery system adds to surgical product options and may support incremental US sales growth.
10 Jul
Bausch + Lomb (BLCO) stock may trade 57% below fair value following recent product updates. Product updates create moderate upside potential for BLCO valuation and near-term market perception.
9 Jul
Bausch + Lomb halts glaucoma eye drop program after trial failure, triggering after-hours drop in BLCO stock. Halting glaucoma eye drop program after trial failure directly weakens Bausch + Lomb pipeline and future revenue outlook.
Bausch + Lomb announced Phase 2 results for its glaucoma neuroprotective candidate. Phase 2 results signal moderate pipeline progress for glaucoma treatment.
Bausch + Lomb launches Orphia, an AI-powered digital health platform designed to return physicians to patient care. Orphia AI platform launch adds digital health capability with moderate effects on innovation and positioning.
30 Jun
Bausch + Lomb faces mixed signals with MyDay contact lens gains offset by Asia-Pacific market pressure, leaving BLCO stock attractiveness in question. MyDay gains and Asia-Pacific pressure may shift short-term sentiment and regional results but are unlikely to alter overall company trajectory.
Bausch + Lomb COO focuses on expanding premium lens sales while addressing operational and market risks in Asia-Pacific region. COO efforts to balance premium lens growth against Asia-Pacific risks indicate moderate effects on company operations and positioning.
9 Jun
Bausch + Lomb launches dry eye product, highlighting company valuation gap and unresolved growth questions. Dry eye launch spotlights valuation gap and growth uncertainties that may influence investor views and near-term positioning.
1 Jun
Bausch + Lomb launches Blink Triple Care Preservative Free Lubricant Eye Drops in the United States. New product launch expands Bausch + Lomb core eye care offerings and supports US market positioning.